Scott Leftwich insider trades
Open-market stock purchases and sales by Scott Leftwich, Director at Calidi Biotherapeutics, Inc, from SEC Form 4 filings since Dec 21, 2023.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -92%.
Recent trades
No open-market trades in the last 12 months.
Companies traded
- CLDI Calidi Biotherapeutics, Inc: 1 buy, last Aug 21, 2025